Data published from a pilot study evaluating 124I-evuzamitide (1 mCi) vs 18F- florbetapir, standard imaging modalities, clinical metrics & HRQoL parameters in patients (n=26) with systemic amyloidosis & healthy volunteers (n=12)
The results acclaimed AL-CMP & ATTRwt-CMP from controls using LV%ID, CAA & TBR & showed a correlation with data for 18F- florbetapir. The ATTRwt patient had a -ve 99mTc-PYP scan, +ve cardiac biopsy for amyloid & +ve cardiac uptake of 124I-evuzamitide
The P-I/II trial evaluating 124I-evuzamitide (<2mg, IV) to detect amyloid deposits by PET/CT imaging in patients (n=50) with different types of systemic amyloidosis. The trial showed cardiac uptake of the radiotracer in all ATTR patients, +ve PET/CT imaging seen in 6 patients & -ve 99mTc-PYP imaging & normal serum NTproBNP levels
Ref: Globenewswire | Image: Attralus
Related News:- Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
